US equities
|
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
NVDA
$233.95
▲+1.34%
MU
$1,074.89
▼-2.05%
TSLA
$370.59
▲+4.65%
SPCX
$158.96
▲+7.35%
SNDK
$1,719.99
▼-3.79%
AMD
$633.91
▲+2.95%
STX
$848.99
▼-10.21%
INTC
$119.33
▼-0.56%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Cullinan Therapeutics, Inc. - Common Stock
(NQ:
CGEM
)
15.51
+0.98 (+6.74%)
Delayed Quote
Updated: 4:00 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Cullinan Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash
↗
November 28, 2025
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.
Via
The Motley Fool
Topics
Lawsuit
Regulatory Compliance
Biotech Fund Reveals $15 Million MoonLake Exit After Stock’s 90% Crash
↗
November 27, 2025
A brutal 90% single-day crash and a shareholder’s full exit raise the stakes for MoonLake’s upcoming FDA meeting.
Via
The Motley Fool
Topics
Lawsuit
Regulatory Compliance
This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones
↗
November 27, 2025
One fast-rising biotech is gearing up for pivotal trials just as a major specialist fund walks away—here’s what long-term investors should take from that divergence.
Via
The Motley Fool
Topics
Initial Public Offering
Regulatory Compliance
Biotech Fund Dumps $12.3 Million in Crinetics Stock as Shares Remain 19% Lower on the Year
↗
November 27, 2025
Here’s what a complete fund exit reveals about sentiment toward one of biotech’s endocrine drug developers.
Via
The Motley Fool
Topics
Regulatory Compliance
Which stocks are experiencing notable movement on Monday?
↗
November 24, 2025
Looking for insights into the US markets one hour before the close of the markets on Monday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Via
Chartmill
Cullinan Therapeutics to Participate in Upcoming Investor Conferences and Host Analyst and Investor Event at 2025 ASH Annual Meeting
November 10, 2025
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) Q3 2025 Earnings Beat Estimates and Announces Strategic Pipeline Refocus
↗
November 06, 2025
Cullinan Therapeutics (CGEM) beat Q3 2025 EPS estimates, announced a strategic pipeline focus, and has cash into 2029.
Via
Chartmill
Topics
Earnings
Cullinan Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results
November 06, 2025
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting
November 03, 2025
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025
October 25, 2025
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics Cancer Drug Shows Efficacy In Brain Metastases Among Lung Cancer Patients With Certain Mutations
↗
October 13, 2025
Zipalertinib shows 31% intracranial response and good tolerability in CNS-involved EGFR-mutated lung cancer, data presented at ESMO 2025.
Via
Benzinga
Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum
September 12, 2025
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
August 21, 2025
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan (CGEM) Q2 R&D Jumps 68%
↗
August 07, 2025
Via
The Motley Fool
CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) Reports Wider Q2 2025 Loss, Misses EPS Estimates Amid Rising R&D Costs
↗
August 07, 2025
Cullinan Therapeutics (CGEM) reported a Q2 2025 net loss of $70.1M (-$1.07/share), missing EPS estimates. Revenue was $0.0. R&D costs rose, but cash reserves remain strong at $510.9M. Stock dipped 2.7%...
Via
Chartmill
Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results
August 07, 2025
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics Stock Slides After-Hours Despite $692M Autoimmune Drug Pact With Genrix
↗
June 05, 2025
Cullinan Therapeutics secured global rights, excluding Greater China, to velinotamig from Genrix Bio, expanding its autoimmune pipeline with a second T cell engager.
Via
Stocktwits
Cullinan Therapeutics Licenses Rights to Velinotamig, a Clinical-Stage BCMA-Directed Bispecific T Cell Engager, from Genrix Bio for Development in Autoimmune Diseases
June 04, 2025
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Host Analyst and Investor Event at 2025 ASCO Annual Meeting and Participate in Jefferies 2025 Global Healthcare Conference
May 29, 2025
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025
May 22, 2025
From
Cullinan Therapeutics, Inc.; Taiho Pharmaceutical Co., Ltd.; Taiho Oncology, Inc.
Via
GlobeNewswire
Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results
May 08, 2025
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Initiate Study of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Sjögren’s Disease in the United States
April 29, 2025
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025
April 23, 2025
Cullinan and Taiho previously announced the Phase 2b portion of the study met the primary endpoint of overall response rate
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Tesla, Nvidia, Apple And Other Big Stocks Moving Lower In Monday's Pre-Market Session
↗
April 21, 2025
Via
Benzinga
Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis
April 16, 2025
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Applied Digital Posts Weak Revenue, Joins Allegro MicroSystems And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
↗
April 15, 2025
Via
Benzinga
Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
February 27, 2025
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
February 24, 2025
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
Cullinan Therapeutics to Participate in Fireside Chat at the Guggenheim Securities SMID Cap Biotech Conference
January 30, 2025
From
Cullinan Therapeutics, Inc.
Via
GlobeNewswire
MicroStrategy, Portland General Electric And Other Big Stocks Moving Lower In Thursday's Pre-Market Session
↗
December 26, 2024
U.S. stock futures were lower this morning, with the Dow futures falling over 100 points on Thursday.
Via
Benzinga
Topics
Stocks
< Previous
1
2
3
4
5
6
7
Next >
